ReviewCytoJournal2022
Screening technologies for cervical cancer: Overview.
Review in CytoJournal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Artificial intelligence-assisted histopathological diagnosis of endocervical gastric-type adenocarcinoma: a multicenter model development and validation study.The journal of pathology. Clinical research · 2026Article
- MXene-APTES-based electrochemical immunosensor for sensitive detection of novel HPV18 E7 oncoprotein.Mikrochimica acta · 2026Article
- Article
- MMTC-Net: Multimodal Temporal Cervical Network for HSIL+ Recognition in Precancer Screening.Journal of imaging informatics in medicine · 2026Article
- Minimal benefit of co-testing over HPV primary screening with cytology triage from resource-limited settings in China.Communications medicine · 2026Article
- Perceived community cervical cancer prevention support and cervical cancer screening utilization among women in Shenzhen, China: a cross-sectional study.Frontiers in public health · 2026Article
- DNMT Enzymes and Their Impact on Cervical Cancer: A State-of-the-Art Review.International journal of molecular sciences · 2025Review
- Evaluating the Cost-Effectiveness of Cervical Cancer Screening and Treatment in Western Romania.Current oncology (Toronto, Ont.) · 2025Article
- HPV-Associated Sexually Transmitted Infections in Cervical Cancer Screening: A Prospective Cohort Study.Viruses · 2025Observational
- Article
- CAPZB mRNA is a novel biomarker for cervical high-grade squamous lesions.Scientific reports · 2024Article
- Telomere Length, Telomerase Activity, and Vaginal Microbiome in Patients with HPV-Related Precancerous Lesions.International journal of molecular sciences · 2024Article
- Evolution of Pathological Techniques for the Screening of Cervical Cancer: A Comprehensive Review.Cureus · 2024Review
- Molecular docking and synthesis of N-alkyl-isatin-3-imino aromatic amine derivatives and their antileishmanial and cytotoxic activities.Research in pharmaceutical sciences · 2024Article
- Can HPV Test on Random Urine Replace Self-HPV Test on Vaginal Self-Samples or Clinician-Collected Cervical Samples?International journal of women's health · 2023Article
- Cervical Cancer in SAARC Countries.South Asian journal of cancer · 2023Article
- Comparison of the performance of HPV DNA chip test and HPV PCR test in cervical cancer screening in rural China.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Ever since the introduction of the Papanicolaou (PAP) smear test was published in 1941 in American Journal of Obstetrics and Gynecology, PAP test linked with definitive treatment has prevented millions of women from cervical cancer in the developed countries. Due to limited availability of resources, a lack of infrastructure and difficulty in getting highly trained professionals, widespread implementation of PAP test dependent cervical cancer screening program has not been established in low and middle income countries such as India. Therefore, after availability of non-cytological tests such as visual inspection on acetic acid (VIA) and human papillomavirus (HPV) DNA test, there is a paradigm shift in cervical cancer screening methods. In past two decades, various research work has convincingly established the utility of VIA and HPV test in developing countries. The evidences were evaluated by the World Health Organization (WHO) and recommendations have been recently published for comprehensive cervical cancer control strategies for the low and middle income countries. For any successful screening program, achieving high coverage (>70%) of the target population rather than frequent screening is the most important determinant. It is also equally important to ensure appropriate investigations of the screen positive women to establish the disease and treatment of the screen detected cases of cervical intra epithelial neoplasia (CIN) and cancer. HPV testing is the WHO recommended test for cervical cancer screening especially in view of widespread HPV vaccination in young population leading to lower prevalence of CIN and other HPV related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.